Cite
HARVARD Citation
Zheng, L. et al. (n.d.). 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer. Journal for immunotherapy of cancer. p. A862. [Online].